About
All Posts
Partner
Logo
Login
Subscribe
Logo
  • Home
  • Posts
  • DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips

Apr 28, 2025

DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips

Bay Area Times
Bay Area Times
DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips

Brought to you by:

Top stories today:

  1. DeepSeek R2 rumored 98%+ cheaper than GPT-4o
  2. Elon’s XAI Holdings said to raise $20B at $120B+ valuation
  3. Huawei said to have developed Ascend 910D to rival NVIDIA’s AI chips
  4. Deel sues Rippling for defamation as rivalry escalates
  5. Neuralink’s ALS patient shares experience regaining communication

Follow us on X | Instagram | Advertise

0. Data and calendar

All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).

All times are ET.

Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):

1. DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips

  • 1.2T parameter size, with 78B active parameters using a hybrid Mixture of Experts (MoE) architecture.

  • 89.8% scores on the C-Eval 2.0 benchmark.

  • 92.4% scores on COCO for vision capabilities.

  • Achieved 82% utilization of Huawei’s Ascend 910B AI chip cluster.

  • TBD: the exact release date.

  • Jan.: DeepSeek disrupted the AI market with its R1 reasoning model release.

2. The protein that might stop arthritis is raising money. Seriously.*

Cytonics

Over 365 million people worldwide suffer from osteoarthritis and there's still no cure, just painkillers and ice packs.

Cytonics’ CYT-108 is a lab-tweaked version of a natural protein (A2M) that blocks the enzymes that eat away at cartilage.

Backed by NIH grants and over 6,000 shareholders, Cytonics is now letting the public invest in its next clinical trial phase.

It’s a shot at finally treating the root cause of joint pain, not just managing it.

Invest in Cytonics and help take down arthritis at the molecular level

*Sponsored by Cytonics ($50,000 contracted). Prospective investors should review the offering materials for details, including all risk factors, before making an investment decision. Any investment involves significant risks, including the potential loss of the total investment. This advertisement is not an offer to sell or a solicitation of an offer to buy securities. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the offering circular before investing in Cytonics.

3. Elon’s XAI Holdings said to raise $20B at $120B+ valuation

Representational image generated using xAI’s Grok.

Subscribe to keep reading

This content is free, but you must be subscribed to Bay Area Times to continue reading.

Already a subscriber?Sign in.Not now

Keep reading

Aug 3, 2026

Qwen3.8-Max debuts as Alibaba’s most capable AI model, rivaling Kimi K3

Qwen3.8-Max debuts as Alibaba’s most capable AI model, rivaling Kimi K3

Jul 31, 2026

Anthropic says Opus 4.7, Mythos 5 breached 3 firms after OpenAI-Hugging Face incident

Anthropic says Opus 4.7, Mythos 5 breached 3 firms after OpenAI-Hugging Face incident

Jul 30, 2026

Microsoft Cloud drives Q4 FY26 revenue +18% YoY to $90B, operating income +18%

Microsoft Cloud drives Q4 FY26 revenue +18% YoY to $90B, operating income +18%

Jul 29, 2026

OpenAI models breached Modal customer before Hugging Face

OpenAI models breached Modal customer before Hugging Face

Subscribe

Your morning briefing, free forever.

Get the latest news, resources, and more delivered straight to your inbox everyday.

The visual daily newsletter on business and tech. Analyzing the news with 1 visual per story. Join our 250,000+ subscribers here.

Copyright Ā© 2026 Bay Area Times.

BAT

Company

Legal

Privacy Policy

Terms of Service